Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Upper Tract Urothelial Carcinomas 1Lymphedema 1Leukemia, Myeloid, Acute 1Leukemia 1Breast Neoplasms 1Adenoma 1

Interventions

Cytarabine 85Cyclophosphamide 58Azacitidine 57fludarabine 52venetoclax 41fludarabine phosphate 41Busulfan 30Filgrastim 23Whole-Body Irradiation 22Decitabine 21Mycophenolic Acid 20Methotrexate 19Mitoxantrone 18Etoposide 18Antilymphocyte Serum 18Cyclosporine 17Clofarabine 17Tacrolimus 16Granulocyte Colony-Stimulating Factor 16Peripheral Blood Stem Cell Transplantation 15Daunorubicin 15Melphalan 13thymoglobulin 11Thiotepa 11Stem Cell Transplantation 11Interleukin-2 11Idarubicin 10Gemtuzumab 9Cord Blood Stem Cell Transplantation 9aldesleukin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Myeloid, Acute × Drug Evaluation × Clear all
NCT05682170 2024-09-19

Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Phase 1/2 Terminated
40 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡